Alpharma, Inc.

Pharmaceutical firm revises third quarter 2004 guidance

Published in Biotech Law Weekly, November 19th, 2004

Alpharma, Inc., announced that it expects results for the third quarter of 2004 to be a loss of approximately $0.10 per diluted share versus the company's guidance of a break even quarter primarily due to a legal settlement and certain inventory and fixed asset write-offs, all related to a U.S. generic nasal spray product.

The results of the company's International Generics, Active Pharmaceutical Ingredients and Animal Health businesses were at or above expectations. In addition, the company expects to report strong third quarter free cash flow and debt to be below second quarter 2004 levels.

The company will update its guidance for the full year...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-11-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry